Table 4.
Incremental cost-effectiveness ratios per DALY averted from PCV13 introduction in alternative scenarios to the base case.
| Direct & indirect population effects | ||
|---|---|---|
| PCV13 (with serotype replacement and herd protection) vs. no PCV | ||
| Societal perspective | Health system perspective | |
| Base case | ||
| Base case | Cost-saving | $52 |
| Cost | ||
| Scenario 1: Vaccine cost using maximum AMC tail price (US$3.50) | Cost-saving | $58 |
| Scenario 2: Vaccine cost using PAHO price (US$15.68) | $390 | $460 |
| Scenario 3: Hospitalization cost using WHO-CHOICE | Cost-saving | $17 |
| Incidence & case fatality risk (Meningitis, Pneumonia, NPNM IPD) | ||
| Scenario 4: Lower bound from regional estimates for Western Pacific [43] | Cost-saving | $180 |
| Scenario 5: Upper bound from regional estimates for Western Pacific [43] | Cost-saving | $10 |
| Direct population effects only | ||
| PCV13 (no serotype replacement, no herd protection) vs. no PCV | ||
| Societal perspective | Health system perspective | |
| Base case | ||
| Base case | $19 | $79 |
| Cost | ||
| Scenario 1: Vaccine cost using maximum AMC tail price (US$3.50) | $26 | $87 |
| Scenario 2: Vaccine cost using PAHO price (US$15.68) | $480 | $540 |
| Scenario 3: Hospitalization cost using WHO-CHOICE | Cost-saving | $27 |
| Incidence & case fatality risk (Meningitis, Pneumonia, NPNM IPD) | ||
| Scenario 4: Lower bound from regional estimates for Western Pacific [43] | $110 | $312 |
| Scenario 5: Upper bound from regional estimates for Western Pacific [43] | Cost-saving | $46 |
Figures are reported to two significant figures for visual clarity.